Program

Friday, January 24, 2025


 

8.30-8.40 Opening 
Heinz Ludwig and Jesús F. San Miguel

 

MYELOMA BIOLOGY AND RISK STRATIFICATION  
Moderator: Heinz Ludwig

8.40-9.00 Evolution patterns from MGUS to multiple myeloma 
Niccolò Bolli

9.00-9.20 The role of the bone marrow microenvironment in the evolution and course of myeloma
Martin Kortüm

9.20-9.40 New risk classification of multiple myeloma
Herve Avet Loiseau

9.40-10.10 Discussion around important questions
    •    Do genomic patterns predict risk of progression of MGUS/SMM
    •    What can be done to strengthen the immune environment
    •    Hurdles for the implementation of the new risk classification
    •    Non-genomic risk classifiers

 

10.10-10.30 BREAK

 

NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT
Moderator: Jesús San Miguel

10.30-10.50 Diagnostic workup of monoclonal gammopathies
Kwee Yong

10.50-11.10 New development in imaging for diagnosis and prognostication
Elena Zamagni 

11.10-11.30 Response assessment – technical and clinical considerations
Bruno Paiva

11.30-12.00 Discussion around important questions
    •    When is a bone marrow biopsy required in MGUS?
    •    Circulating plasma cells for disease and response assessment
    •    Optimizing imaging technologies – MRI and PET/CT
    •    Comparison of different mass spectrometry techniques (MALDI-TOF, clonotypic peptide detection approach)
    •    Is MRD assessment in MGUS-like MM useful?

 

WORKSHOPS 

12.00-12.30 Prevention and treatment of bone disease
Evangelos Terpos

12.00-12.30 Prevention and Management of infections in multiple myeloma
Heinz Ludwig

12.00-12.30 Management of extramedullary myeloma, solitary plasmocytoma and plasma cell leukemia
Meral Beksac

 

12.30- 13.30 LUNCH

 

MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE
Moderator: Heinz Ludwig

13.30-13.50 High risk smoldering myeloma: to treat or not to treat
Mario Boccadoro

13.50-14.10 Quadruplets and beyond for first line therapy of transplant eligible patients
Philippe Moreau

14.10-14.30 Game changing results from recent EMN trials
Pieter Sonneveld

14.30-14.50 Maintenance treatment with lenalidomide and beyond
Francesca Gay

14.50-15.20 Discussion around important questions
    •    Can the prediction of early progression in SMM be further improved?
    •    Can upfront ASCT be deferred or abandoned in good risk patients in the era of novel quadruplets?
    •    What is the optimal number of induction and consolidation cycles?
    •    MRD guide therapy ready for prime time?
    •    New concepts for maintenance therapy

 

15.20-15.40 BREAK

 

MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS
Moderator: Jesús San Miguel

15.40-16.00 The impact of frailty and comorbidities on treatment selection
Charlotte Pawlyn

16.00-16.20 Treatment of TNE patients, today and tomorrow
Thierry Facon

16.20-16.50 Discussion of important questions
    •    Treatment of very elderly patients
    •    How to distinguish between myeloma and patients related comorbidities?
    •    Initiation of therapy at biochemical progression?
    •    Treatment duration
    •    Impact of patient risk factors on treatment selection

 

16.50- 17.00 BREAK

17.00-17.30 WORKSHOPS (repeated)

 

KEYNOTE LECTURE

17.30-18.00 Important milestones in the management of multiple myeloma and strategies for further advancements
Jesús San Miguel

 

 

Saturday, January 25, 2025


 

THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE
Moderator: Jesús San Miguel

8.30-8.50 How to select treatment after relapse
Maria-Victoria Mateos

8.50-9.10 My approach to patients with high-risk disease
Martin Kaiser 

9.10-9.30 Indications for less frequently used drugs including Blenrep, Selinexor, Melflufen, Venetoclax and new IMiDs 
Evangelos Terpos
 

9.30-10.00 Discussion of important questions
    •    Limitations of the definition of refractoriness 
    •    Management of early relapse
    •    Lenalidomide refractory patients
    •    CD38 retreatment
    •    Optimizing therapy in high-risk RRMM patients

 

10.00-10.20 BREAK

 

HOT TOPICS IN MYELOMA
Moderator: Heinz Ludwig

10.20-10.40 How to optimize use of bispecific antibodies
Niels van de Donk

10.40-11.00 Cellular therapies in MM, present options and outlook
Hermann Einsele

11.00-11.30 Discussion of important questions
    •    Is there a preferred target for BsAbs and CAR-T cells?
    •    Pros and cons for BsAbs or CAR-T cells
    •    Impact of CAR-T cell persistence on outcome
    •    Prevention of toxicities of BsAbs and CAR-T cells

 

AMYLOIDOSIS AND WADENSTRÖM’S DISEASE
Moderator: Heinz Ludwig

11.30-11.50 Treatment approaches in Waldenström’s disease
Meletios A. Dimopoulos

11.50-12.10 Recent developments Amyloidosis research and therapy
Giovanni Palladini

12.10-12.40 Discussion of important questions
    •    Is cure a realistic goal in amyloidosis?
    •    Cellular therapies in amyloidosis
    •    Treatment of patients failing to first-line treatment with BTK inhibitors and CD20+ based therapies
    •    Is there a role for anti-BCMA treatments in Waldenström’s disease as 2/3 express BCMA on their tumor clones? 

 

12.40-12.50 Closure of the meeting
Heinz Ludwig